Share on StockTwits
 

Tetraphase Pharmaceuticals (NASDAQ:TTPH) CFO David Charles Lubner sold 9,928 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $14.22, for a total transaction of $141,176.16. Following the completion of the transaction, the chief financial officer now directly owns 101,009 shares in the company, valued at approximately $1,436,348. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

TTPH has been the subject of a number of recent research reports. Analysts at Barclays raised their price target on shares of Tetraphase Pharmaceuticals from $16.00 to $17.00 in a research note on Friday, January 10th. They now have an “overweight” rating on the stock. Analysts at Guggenheim initiated coverage on shares of Tetraphase Pharmaceuticals in a research note on Wednesday, November 13th. They set a “buy” rating and a $25.00 price target on the stock. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $17.33.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded down 0.35% on Tuesday, hitting $14.29. 748,154 shares of the company’s stock traded hands. Tetraphase Pharmaceuticals has a one year low of $7.00 and a one year high of $17.74. The stock’s 50-day moving average is $14.96 and its 200-day moving average is $11.65. The company’s market cap is $359.8 million.

Tetraphase Pharmaceuticals, Inc, incorporated on July 7, 2006, is a clinical stage biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.